Gilead Licenses Long-Acting HIV Prevention Drug
Gilead signs agreements to facilitate access to HIV prevention drug
Gilead Sciences has announced the signing of voluntary licencing agreements with six generic pharmaceutical manufacturers to facilitate access to lenacapavir, a potential human immunodeficiency virus (HIV) prevention drug,
Gilead Partners With Generics Developers to Provide HIV Drug to Low-Income Countries
Gilead Sciences is granting licenses to six companies to produce lenacapavir for pre-exposure prophylaxis, as well as for treating human immunodeficiency virus in heavily pre-treated adults with multidrug-resistant infections.
Gilead licenses anti-HIV drug to generic drugmakers
United States pharmaceutical giant Gilead said on Wednesday it had signed licensing deals with six generic drugmakers to produce and sell its human immunodeficiency virus (HIV) prevention medicine in lower-income countries.
Gilead's tie up with generic cos may not address HIV challenge
Gilead's partnership with generic manufacturers to lower the cost of its HIV drug lenacapavir is criticized for being too restrictive. Key countries w
Gilead strikes voluntary licensing deals in poor countries for its pricey HIV drug
Gilead will license the HIV drug lenacapavir, a twice-yearly injectable, to six generic makers for 120 countries.
Gilead strikes licensing deals with 6 generics makers to boost access to long-acting HIV PrEP med
Gilead Sciences is wasting no time in promoting worldwide access to its twice-yearly pre-exposure prophylaxis (PrEP) HIV candidate lenacapavir. | The company will allow six generic manufacturers to make and sell its long-acting PrEP drug,
Biopharma firm Gilead announces lenacapavir licensing for HIV treatment
International AIDS Society, an association of HIV/AIDS professionals, applauded moves by Gilead Sciences, a biopharma company, to make the generic injectable lenacapavir for HIV prevention widely available, but cautioned that the current agreements still leave out millions around the world.
Gilead Licenses Long-Acting HIV Prevention Drug to Generics Firms
Gilead Sciences Inc. said it is licensing its twice-yearly experimental HIV prevention drug lenacapavir to six generics makers after coming under fire from HIV advocates who argued the company was prioritizing profit over patients.
Gilead Licenses HIV-prevention Drug To Generic Drugmakers
US pharmaceutical giant Gilead said Wednesday it had signed licensing deals with six generic drugmakers to produce and sell its HIV prevention medicine in lower-income countries.
Gilead Agrees to Allow Generic Version of Groundbreaking H.I.V. Shot in Poor Countries
The drugmaker Gilead Sciences on Wednesday announced a plan to allow six generic pharmaceutical companies in Asia and North ...
India Infoline2h
Hetero Partners with Gilead to Expand Global Access to HIV Drug Lenacapavir
The collaboration supports efforts for HIV prevention through PrEP, emphasizing Hetero’s commitment to improving HIV care.
Gilead inks pact with six generic drugmakers on long-acting HIV injectable, even as civil society oppose patent application
Six drugmakers sign agreements with Gilead Sciences to produce generic lenacapavir, a long-acting HIV drug, amid patent ...
Armed robbery in Revesby1d
UNAIDS Reacts to Gilead's Lenacapavir Licensing Deal
Responding to today's announcement by Gilead on lenacapavir, UNAIDS Executive Director Winnie Byanyima said:"We welcome ...
emjreviews.com19h
Gilead expands access to PrEP HIV candidate in 120 countries
A new licensing agreement from Gilead Sciences and six generic drug manufacturers is poised to transform HIV prevention ...